Company Profiles

driven by the PitchBook Platform

Arsanis

Description

Developer of monoclonal antibodies (mAbs) designed to prevent and treat serious infectious diseases. The company's monoclonal antibodies (mAbs) has transformed the treatment of a wide range of diseases from cancer to immune system disorders, it can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes, enabling physicians to redefining the practice of medicine for serious infections.

2010

Founded

PRIVATE

Status

11-50

Employees

Series D

Latest Deal Type

$45.5M

Latest Deal Amount

$90.5M

Total Amount Raised

Description

Developer of monoclonal antibodies (mAbs) designed to prevent and treat serious infectious diseases. The company's monoclonal antibodies (mAbs) has transformed the treatment of a wide range of diseases from cancer to immune system disorders, it can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes, enabling physicians to redefining the practice of medicine for serious infections.

Website:

www.arsanis.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

890 Winter Street Suite 230 Waltham, MA 02451United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Arsanis's full profile, request a free trial.

    Arsanis Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Arsanis Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Arsanis Investors (9)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Alexandria Venture InvestmentsVenture CapitalMinority000 0000000 0000
    Anna Maria And Stephen Kellen FoundationOtherMinority000 0000000 0000
    Bill & Melinda Gates FoundationNot-For-Profit Venture CapitalMinority000 0000000 0000
    EMBL VenturesVenture CapitalMinority000 0000000 0000
    GVCorporate Venture CapitalMinority000 0000000 0000
    Alexandria Venture Investments Venture Capital
    Anna Maria And Stephen Kellen Foundation Other
    Bill & Melinda Gates Foundation Not-For-Profit Venture Capital
    EMBL Ventures Venture Capital
    GV Corporate Venture Capital

    Arsanis Executive Team (6)

    NameTitleBoard
    Seat
    Contact
    Info
    Eszter Nagy Ph.DCo-Founder, Managing Director, Board Member & Chief Scientific Officer
    Rene RussoPresident, Board Member & Chief Executive Officer
    Michael GrayChief Financial Officer & Chief Business Officer
    David Mantus Ph.DChief Development Officer
    Steven Luperchio Ph.DDirector of Clinical and Medical Research
    Eszter Nagy Ph.D Co-Founder, Managing Director, Board Member & Chief Scientific Officer
    Rene Russo President, Board Member & Chief Executive Officer
    Michael Gray Chief Financial Officer & Chief Business Officer
    David Mantus Ph.D Chief Development Officer
    Steven Luperchio Ph.D Director of Clinical and Medical Research

    Arsanis Board Members (10)

    NameRepresentingRoleSinceContact
    Info
    Amy Schulman JDPolaris PartnersVenture Partner000 0000
    Carl Gordon Ph.DOrbiMedFounding Partner & Co-Head of Global Private Equity000 0000
    Claudio Nessi Ph.DNeoMed ManagementManaging Partner000 0000
    Daniel BurgessSV Health InvestorsVenture Partner000 0000
    Eszter Nagy Ph.DArsanisCo-Founder, Managing Director, Board Member & Chief Scientific Officer000 0000
    Amy Schulman JD Venture Partner Polaris Partners
    Carl Gordon Ph.D Founding Partner & Co-Head of Global Private Equity OrbiMed
    Claudio Nessi Ph.D Managing Partner NeoMed Management
    Daniel Burgess Venture Partner SV Health Investors
    Eszter Nagy Ph.D Co-Founder, Managing Director, Board Member & Chief Scientific Officer Arsanis
    Request full access to PitchBook